Trial reportNature communications2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
Trial report in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03158129 (Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection), which is not on this map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Who cites it
59 citing papers in PubMed, 104 citations in OpenAlex.
- Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.International journal of cancer · 2026Trial
- Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.American journal of clinical oncology · 2026Trial
- Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.Breast cancer research and treatment · 2025Trial
- High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.Journal for immunotherapy of cancer · 2024Trial
- Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.BMC medicine · 2022Trial
- Robotic versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Cancer After Neoadjuvant Therapy: A Dual-Center Retrospective Study.Annals of surgical oncology · 2026Article
- Article
- Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET-CT-based study.ESMO open · 2026Article
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.Nature reviews. Clinical oncology · 2026Review
- Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study.Chinese medical journal · 2026Article
- Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis.Apoptosis : an international journal on programmed cell death · 2026Article
- Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review.Cancers · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Article
- The value of positron emission tomography scan in predicting pathologic response of non-small cell lung cancer managed by neoadjuvant chemo-immunotherapy.Journal of thoracic disease · 2026Article
- [Clinical Significance of Extranodal Extension in Non-small Cell Lung Cancer: Current Status and Future Prospects].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- [Pseudoprogression after start of immunotherapy].Radiologie (Heidelberg, Germany) · 2026Review
- Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [European radiology · 2025Article
- Surgical audience focused on multimodality treatment for lung cancer.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Review
- Immunotherapy for resectable lung cancer.Cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 1 institution in 2 countries.
Funding
Abstract
Radiographic imaging is the standard approach for evaluating the disease involvement of lymph nodes in patients with operable NSCLC although the impact of neoadjuvant immune checkpoint inhibitors (ICIs) on lymph nodes has not yet been characterized. Herein, we present an ad hoc analysis of the NEOSTAR trial (NCT03158129) where we observed a phenomenon we refer to as "nodal immune flare" (NIF) in which patients treated with neoadjuvant ICIs demonstrate radiologically abnormal nodes post-therapy that upon pathological evaluation are devoid of cancer and demonstrate de novo non-caseating granulomas. Abnormal lymph nodes are analyzed by computed tomography and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.